Covi-Pantel . NZ Trader Release, page-1130

For those that are interested here is some weekend reading. There seems to be a bit more interest in this stuff lately I have posted it before

http://pharmaust.com/wp-content/uploads/2017/11/150908_Actuity_-PHARMAUST-valuation-08-09-15signed.pdf

A couple of extracts reguarding MPL

In a licensing deal the net gains from commercialising the IP are
generally split between licensee and licensor, often in a ratio of four to one, the “25% rule”, and
possibly up to 50:50 depending on the status of a project at the time the transaction is entered. In
the current analyses we have apportioned 66.7% of net benefit (defined as Net Profit Before Tax,
“NPBT”) to the licensee and 33.3% to the licensor on the basis that the Company will have a
strong negotiating position following successful proof-of-efficacy in humans, and animals for the
veterinary product, on completion of Phase I and Phase II studies.

So that is a bit better than a licencing deal for the patent holder. Actuity are talking about ownership of IP there. Bear in mind this valuation was done about 6 years ago there are only about 34 months until Elanco's patents run out.

There is a heap of other stuff in there that PickEm and kpax have been touching on re possible uses/ patents
MPL seems like the new age revolutionary molecule. Probably as an important discovery a penicillin IMO and here we are on the ground floor.

The other two treatments have been traded back to Sydney Uni

Good luck to all